Establishing a new standard for the life science industry: SHS supports internationalization and further growth of Single Use Support
- As a solution provider for the life science industry, Single Use Support (SUS) increases patient safety and minimizes the risk of contamination
- SUS customers include well-known companies from Europe, Asia and America
- SUS platform technology can become the industry standard for fluid logistics processes in the life science, biotech, pharmaceutical and medical device industries
The medical technology and life science investor SHS Gesellschaft für Beteiligungsmanagement, based in Tübingen, Germany, has acquired a stake in Single Use Support GmbH (SUS) within the framework of a capital increase. With the support of SHS, the technology company based in Kufstein, Austria, intends to further advance its international growth and expand its sales structures.
SUS develops and manufactures mechatronic systems and consumables for fluid logistics processes in the life science, biotech and pharmaceutical industries. The flexible and scalable platform developed by SUS enables the safe, sterile and deep-frozen transport of high-value, vital drugs around the globe in single-use bags from various manufacturers, thus solving a major interface problem for the research and development departments of the biopharmaceutical industry as well as the producers of approved drugs in the handling of frozen liquid substances and with regard to the integrity of single-use systems – a problem that is perceived as relevant by various regulatory authorities, for example in the USA. The SUS products range from devices for testing the leak-tightness of transport containers, filling and freezing liquids to controlled defrosting and removal at the destination. The liquids are transported in bags of different sizes using the company’s own transport system. The SUS platform has the potential to become the new industry standard in a rapidly growing market.
The company’s customers are well-known corporations in Europe, Asia and America. Just a few weeks ago, the Kufstein-based company announced several major orders from large customers in the biopharmaceutical industry. For example, a well-known Swiss group ordered Single Use Support systems for the filling, controlled freezing and thawing of quality substances with a total value of €1.2 million.
Since the company was founded in 2015, SUS management has driven dynamic growth while maintaining profitability. Turnover has more than doubled each year. The investment by SHS is intended to further accelerate growth to establish logistics and sales structures – also internationally – more quickly and to be even closer to customers. This expansion will particularly focus on the USA, as numerous target customers are based there and the company is already working successfully with US customers.
“We enable biotech companies to access an innovative and highly secure fluid logistics process,” said Johannes Kirchmair and Thomas Wurm, Founders and Managing Directors of SUS, “The technologies we have developed increase patient safety and minimize the risk of contamination and product loss. During the investment process, SHS proved to be a professional and reliable partner. We have been impressed with the company’s network and many years of experience in supporting growth companies. We are glad to have SHS on board as a strong partner.”
“By investing in SUS, we are consistently pursuing our investment strategy of supporting dynamically growing life science companies with capital and know-how. With SUS, we have found such a company that is led by two top industry experts and has the potential to set new standards in its industry. We are looking forward to supporting the team as the company grows,” says Uwe Steinbacher, Managing Partner at SHS.
About SHS Gesellschaft für Beteiligungsmanagement mbH
SHS Gesellschaft für Beteiligungsmanagement is based in Tübingen, Germany, and invests in medical technology and life science companies with a focus on expansion financing, changes in shareholder structures and successor situations. SHS holds minority as well as majority interests. The company was founded in 1993 and has since gained extensive experience as an industry investor, which supports the growth of its portfolio companies through a network of partnerships regarding the introduction of new products, regulatory issues or entering new markets. The SHS fund’s German and international investors include professional pension insurers, retirement funds, strategic investors, funds of funds, family offices, entrepreneurs and the SHS management team. The AIFM-registered company invests up to €30 million in equity capital and volumes exceeding this amount are implemented with a network of co-investors. SHS is currently investing from its fifth fund. The fund has received capital commitments of more than €130 million. Further information: https://www.shs-capital.eu
Are you interested in receiving regular updates about SHS? Subscribe to our newsletter!
Dr. Reinhard Saller
IWK Communication Partner
Tel.: +49 (0) 89 2000 3030
Fax: +49 (0) 89 2000 3040